Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infanrix + VAQTA
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Infanrix + VAQTA refers to the concomitant administration of two distinct vaccine products: **Infanrix**, a diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine developed by GSK, and **VAQTA**, an inactivated hepatitis A vaccine developed by Merck Sharp & Dohme. This specific combination was evaluated in Phase 4 clinical trials (such as NCT00289913) to assess the safety, tolerability, and immunogenicity of concomitant administration in healthy children aged 12 to 17 months. Infanrix provides active immunity against diphtheria, tetanus, and pertussis through the use of toxoids and purified pertussis antigens, while VAQTA provides active immunity against the hepatitis A virus using a highly purified, formaldehyde-inactivated virus. The combination is intended to simplify pediatric immunization schedules by allowing multiple protections to be delivered during a single clinical visit.
- Other names
- DTaP vaccine + Hepatitis A vaccine (inactivated)
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Infanrix + VAQTA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infanrix + VAQTA.